1. Home
  2. MINE vs AGEN Comparison

MINE vs AGEN Comparison

Compare MINE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mayfair Gold Corp. Common Shares

MINE

Mayfair Gold Corp. Common Shares

N/A

Current Price

$2.32

Market Cap

163.8M

Sector

Energy

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$5.98

Market Cap

208.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MINE
AGEN
Founded
2019
1994
Country
Canada
United States
Employees
9
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.8M
208.2M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
MINE
AGEN
Price
$2.32
$5.98
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
22.7K
8.2M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.11
Revenue Growth
N/A
89.95
52 Week Low
$2.16
$2.71
52 Week High
$4.45
$8.70

Technical Indicators

Market Signals
Indicator
MINE
AGEN
Relative Strength Index (RSI) 42.03 68.65
Support Level $2.21 $3.16
Resistance Level $2.87 $8.70
Average True Range (ATR) 0.14 0.77
MACD 0.02 0.18
Stochastic Oscillator 2.94 50.00

Price Performance

Historical Comparison
MINE
AGEN

About MINE Mayfair Gold Corp. Common Shares

Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: